|
?:abstract
|
-
The primary cause of morbidity and mortality in patients with multiple myeloma(MM) is an infection Therefore there is great concern about the susceptibility to the outcome of COVID-19 infected patients with MM This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during COVID-19 pandemic Analysis were performed for hospitalized MM patients Among hospitalized patinets, the median age was 69 years, and nearly all patients(96%) had MM Approximately 36% were recently diagnosed(2019-2020), and 54% of patients were receiving first-line therapy Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients Univariate analysis identified age, ISS3, high-risk disease, renal disease, suboptimal myeloma control(active or progressive disease), and one or more comorbidities as risk factors for higher rates of death Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection The management of MM in the era of COVID-19 requires careful consideration of patient and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}